Enliven Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Enliven Therapeutics has a total shareholder equity of $304.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $327.0M and $22.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$312.39m |
| Equity | US$304.93m |
| Total liabilities | US$22.11m |
| Total assets | US$327.04m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: ELVN's short term assets ($318.1M) exceed its short term liabilities ($22.1M).
Long Term Liabilities: ELVN's short term assets ($318.1M) exceed its long term liabilities ($6.0K).
Debt to Equity History and Analysis
Debt Level: ELVN is debt free.
Reducing Debt: ELVN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELVN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ELVN has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 43% each year.